How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
30
CSTL Quote, Financials, Valuation and Earnings
Last price:
$32.77
Seasonality move
:
-24.76%
Day range:
$31.64 - $33.31
52-week range:
$14.59 - $44.28
Dividend yield:
0%
P/E ratio:
30.24x
P/S ratio:
2.80x
P/B ratio:
2.05x
Volume:
556.5K
Avg. volume:
382.2K
1-year change:
17.68%
Market cap:
$955.9M
Revenue:
$332.1M
EPS (TTM):
-$0.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$80.4M | -$0.24 | -12.07% | -55.29% | $48.57 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$232.2M | $2.01 | 5.9% | 130.85% | $110.38 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.34% | 90.44% | $14.86 |
|
CTSO
CytoSorbents Corp.
|
$9.2M | -$0.07 | 11% | -41.38% | $5.25 |
|
DCTH
Delcath Systems, Inc.
|
$20.4M | -$0.03 | 23.67% | 56.83% | $22.33 |
|
ODYY
Odyssey Health, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$32.75 | $48.57 | $955.9M | 30.24x | $0.00 | 0% | 2.80x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$81.84 | $110.38 | $1.8B | 50.19x | $0.00 | 0% | 2.00x |
|
CRMD
CorMedix, Inc.
|
$7.69 | $14.86 | $605.9M | 3.75x | $0.00 | 0% | 2.59x |
|
CTSO
CytoSorbents Corp.
|
$0.67 | $5.25 | $42.2M | -- | $0.00 | 0% | 1.20x |
|
DCTH
Delcath Systems, Inc.
|
$9.37 | $22.33 | $330.9M | 1,077.01x | $0.00 | 0% | 4.47x |
|
ODYY
Odyssey Health, Inc.
|
$0.0600 | -- | $6M | 0.41x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
7.37% | 0.721 | 5.59% | 6.09x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.779 | 30.7% | 2.40x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
CTSO
CytoSorbents Corp.
|
75.25% | 1.103 | 46.74% | 1.49x |
|
DCTH
Delcath Systems, Inc.
|
0.83% | 1.664 | 0.25% | 12.82x |
|
ODYY
Odyssey Health, Inc.
|
-38.09% | 10.273 | 26.6% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSTL
Castle Biosciences, Inc.
|
$61.5M | -$6.8M | -2.54% | -2.71% | -8.19% | $7.8M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
CTSO
CytoSorbents Corp.
|
$6.7M | -$2.7M | -27.15% | -89.32% | -28.07% | -$2.5M |
|
DCTH
Delcath Systems, Inc.
|
$17.9M | -$388K | 1.56% | 1.59% | -1.89% | $4.3M |
|
ODYY
Odyssey Health, Inc.
|
-- | -$303.2K | -- | -- | -- | -$284K |
Castle Biosciences, Inc. vs. Competitors
-
Which has Higher Returns CSTL or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 10.59%. Castle Biosciences, Inc.'s return on equity of -2.71% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About CSTL or ANIP?
Castle Biosciences, Inc. has a consensus price target of $48.57, signalling upside risk potential of 48.31%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.38 which suggests that it could grow by 34.87%. Given that Castle Biosciences, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Castle Biosciences, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is CSTL or ANIP More Risky?
Castle Biosciences, Inc. has a beta of 1.062, which suggesting that the stock is 6.16% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.500, suggesting its less volatile than the S&P 500 by 50.037%.
-
Which is a Better Dividend Stock CSTL or ANIP?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSTL or ANIP?
Castle Biosciences, Inc. quarterly revenues are $83M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Castle Biosciences, Inc.'s net income of -$501K is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while ANI Pharmaceuticals, Inc.'s PE ratio is 50.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 2.80x versus 2.00x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.2.80x 30.24x $83M -$501K ANIPANI Pharmaceuticals, Inc.2.00x 50.19x $227.8M $24.1M
-
Which has Higher Returns CSTL or CRMD?
CorMedix, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 49.9%. Castle Biosciences, Inc.'s return on equity of -2.71% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About CSTL or CRMD?
Castle Biosciences, Inc. has a consensus price target of $48.57, signalling upside risk potential of 48.31%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 93.2%. Given that CorMedix, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe CorMedix, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 CRMDCorMedix, Inc.4 0 0 -
Is CSTL or CRMD More Risky?
Castle Biosciences, Inc. has a beta of 1.062, which suggesting that the stock is 6.16% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock CSTL or CRMD?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or CRMD?
Castle Biosciences, Inc. quarterly revenues are $83M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Castle Biosciences, Inc.'s net income of -$501K is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while CorMedix, Inc.'s PE ratio is 3.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 2.80x versus 2.59x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.2.80x 30.24x $83M -$501K CRMDCorMedix, Inc.2.59x 3.75x $104.3M $108.6M
-
Which has Higher Returns CSTL or CTSO?
CytoSorbents Corp. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of -33.42%. Castle Biosciences, Inc.'s return on equity of -2.71% beat CytoSorbents Corp.'s return on equity of -89.32%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M CTSOCytoSorbents Corp.70.28% -$0.05 $36.4M -
What do Analysts Say About CSTL or CTSO?
Castle Biosciences, Inc. has a consensus price target of $48.57, signalling upside risk potential of 48.31%. On the other hand CytoSorbents Corp. has an analysts' consensus of $5.25 which suggests that it could grow by 681.25%. Given that CytoSorbents Corp. has higher upside potential than Castle Biosciences, Inc., analysts believe CytoSorbents Corp. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 CTSOCytoSorbents Corp.1 1 0 -
Is CSTL or CTSO More Risky?
Castle Biosciences, Inc. has a beta of 1.062, which suggesting that the stock is 6.16% more volatile than S&P 500. In comparison CytoSorbents Corp. has a beta of 1.393, suggesting its more volatile than the S&P 500 by 39.333%.
-
Which is a Better Dividend Stock CSTL or CTSO?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. CytoSorbents Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or CTSO?
Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than CytoSorbents Corp. quarterly revenues of $9.5M. Castle Biosciences, Inc.'s net income of -$501K is higher than CytoSorbents Corp.'s net income of -$3.2M. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while CytoSorbents Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 2.80x versus 1.20x for CytoSorbents Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.2.80x 30.24x $83M -$501K CTSOCytoSorbents Corp.1.20x -- $9.5M -$3.2M
-
Which has Higher Returns CSTL or DCTH?
Delcath Systems, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of 4.04%. Castle Biosciences, Inc.'s return on equity of -2.71% beat Delcath Systems, Inc.'s return on equity of 1.59%.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M DCTHDelcath Systems, Inc.87.24% $0.02 $115.8M -
What do Analysts Say About CSTL or DCTH?
Castle Biosciences, Inc. has a consensus price target of $48.57, signalling upside risk potential of 48.31%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.33 which suggests that it could grow by 138.35%. Given that Delcath Systems, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe Delcath Systems, Inc. is more attractive than Castle Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 DCTHDelcath Systems, Inc.5 0 0 -
Is CSTL or DCTH More Risky?
Castle Biosciences, Inc. has a beta of 1.062, which suggesting that the stock is 6.16% more volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.373, suggesting its less volatile than the S&P 500 by 62.663%.
-
Which is a Better Dividend Stock CSTL or DCTH?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or DCTH?
Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than Delcath Systems, Inc. quarterly revenues of $20.6M. Castle Biosciences, Inc.'s net income of -$501K is lower than Delcath Systems, Inc.'s net income of $830K. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Delcath Systems, Inc.'s PE ratio is 1,077.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 2.80x versus 4.47x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.2.80x 30.24x $83M -$501K DCTHDelcath Systems, Inc.4.47x 1,077.01x $20.6M $830K
-
Which has Higher Returns CSTL or ODYY?
Odyssey Health, Inc. has a net margin of -0.6% compared to Castle Biosciences, Inc.'s net margin of --. Castle Biosciences, Inc.'s return on equity of -2.71% beat Odyssey Health, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M ODYYOdyssey Health, Inc.-- -$0.00 -$5.2M -
What do Analysts Say About CSTL or ODYY?
Castle Biosciences, Inc. has a consensus price target of $48.57, signalling upside risk potential of 48.31%. On the other hand Odyssey Health, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Castle Biosciences, Inc. has higher upside potential than Odyssey Health, Inc., analysts believe Castle Biosciences, Inc. is more attractive than Odyssey Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSTLCastle Biosciences, Inc.8 0 0 ODYYOdyssey Health, Inc.0 0 0 -
Is CSTL or ODYY More Risky?
Castle Biosciences, Inc. has a beta of 1.062, which suggesting that the stock is 6.16% more volatile than S&P 500. In comparison Odyssey Health, Inc. has a beta of -1.030, suggesting its less volatile than the S&P 500 by 202.982%.
-
Which is a Better Dividend Stock CSTL or ODYY?
Castle Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Odyssey Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences, Inc. pays -- of its earnings as a dividend. Odyssey Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSTL or ODYY?
Castle Biosciences, Inc. quarterly revenues are $83M, which are larger than Odyssey Health, Inc. quarterly revenues of --. Castle Biosciences, Inc.'s net income of -$501K is lower than Odyssey Health, Inc.'s net income of -$483.4K. Notably, Castle Biosciences, Inc.'s price-to-earnings ratio is 30.24x while Odyssey Health, Inc.'s PE ratio is 0.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences, Inc. is 2.80x versus -- for Odyssey Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSTLCastle Biosciences, Inc.2.80x 30.24x $83M -$501K ODYYOdyssey Health, Inc.-- 0.41x -- -$483.4K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
